Fabtech Technologies Limited – Investor Presentation Summary

Key Operational Highlights

  • Order book of ₹900+ crore as of September 30, 2026 (2.2x FY26 Revenue)
  • 2000+ specialized installations across 62+ countries with 500+ projects delivered
  • 75-80% of revenue from MENA, GCC & ECO Zone markets
  • New market entry into CIS country with turnkey design-and-build project
  • Africa initiatives gaining momentum including cell and gene therapy (CGT) and advanced-technology facility projects

Key drivers of operational performance: Global execution capabilities, in-house manufacturing control, integrated engineering platform covering Process, Air & Water systems.

Segment-wise Performance

Geographic Revenue Mix H1FY27:

  • Saudi Arabia: ₹462.3 million (+18.5% YoY)
  • Africa: ~₹470 million (Morocco, Kenya & Algeria combined)
  • Core FTL Business: Showing turnaround with strong standalone recovery

Explanation of significant changes in segment performance: Strong performance in Saudi Arabia driven by continued project execution, while Africa initiatives are gaining momentum with expected significant contribution to H2 project execution and revenue.

Financial Highlights

Revenue: Rs. 920.9 million (Q2 FY27), Rs. 1,670.7 million (H1 FY27)

EBITDA: Rs. 155.7 million (Q2 FY27), Rs. 229.8 million (H1 FY27)

PAT: Rs. 150.2 million (Q2 FY27), Rs. 192.4 million (H1 FY27)

Adjusted PAT: Rs. 84.3 million (Q2 FY27), Rs. 126.5 million (H1 FY27)

EPS: Rs. 3.38 (Q2 FY27), Rs. 4.33 (H1 FY27)

Margins: EBITDA Margin 16.0% (Q2 FY27), 13.1% (H1 FY27); Reported PAT Margin 16.3% (Q2 FY27), 11.5% (H1 FY27); Adjusted PAT Margin 9.2% (Q2 FY27), 7.6% (H1 FY27)

YoY/QoQ comparison: Q2 Revenue down 24.2% YoY but up 22.8% QoQ; Q2 EBITDA down 53.2% YoY but up 110.0% QoQ; Q2 Reported PAT down 46.6% YoY but up 256.9% QoQ

Drivers of financial performance: Improved project execution, strong EBITDA growth despite revenue decline, significant other income increase (72.2% QoQ in Q2)

Key Risks: Geopolitical uncertainty, freight volatility across GCC markets, higher installation costs due to enhanced security measures

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Primary operations across India, GCC, Africa, and entering CIS countries

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Other Equity ₹3,946.3 million (H1FY27)

Current Assets/Liabilities: Current Assets ₹5,692.6 million vs Current Liabilities ₹2,206.8 million (H1FY27)

Working Capital/Leverage Metrics: Trade Receivables ₹2,261.0 million; Inventories ₹184.8 million; Trade Payables ₹836.5 million (H1FY27)

Financial Health Insights: Strong cash position of ₹1,699.7 million; Reduced short-term borrowings to ₹309.0 million from ₹422.0 million (FY26)

Capex & Cash Flow Health

Capital Expenditure: Not Specified

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Short-term borrowings reduced to ₹309.0 million from ₹422.0 million (FY26)

Investment Rationale: Focus on capacity expansion, technology upgrades, and global market expansion

Strategic & R&D Initiatives

Investments in Innovation: Advance capabilities in cell and gene therapy facilities, other high-technology projects and data-centre infrastructure; Fabtech 4.0 initiative for technology-enabled project delivery

Expected impact on growth: Positioning for large-scale biotech tenders and advanced facility projects

Strategic Rationale: Expanding into high-growth markets (Africa, CIS, Europe), reducing operational costs through integrated execution model

Industry Trends & Business Environment

Macro/Industry Trends: Pharma and healthcare manufacturing capacity expansion across emerging markets; Healthcare localization creating larger opportunities; Countries building domestic pharmaceutical manufacturing capabilities

Impact on Company: Creating structural healthcare capex opportunities; Expanding total addressable market covering 60%+ of project spend in Air, Water, Process, Cleanrooms and Utilities

Management Commentary & Growth Outlook

Strategic Outlook: Revenue and profitability expected to improve as planned project milestones translate into execution during H2 FY27

FY Guidance: Management confident of achieving FY27 Adjusted PAT margin objective of 8-9%

Market Share Targets: Not Specified

Risks and Opportunities: Navigating geopolitical uncertainty and freight volatility; Exploring operational opportunity in Europe targeting Q4 FY27 or Q1 FY28

ESG Updates

Not Specified

Digital Transformation

Fabtech 4.0: Moving from engineering execution to technology-enabled project delivery through Project Intelligence, Integrated Procurement, and Global Collaboration